Close Menu

Colorectal Cancer

News and reporting on colorectal cancer.

An international research team suggests high-resolution melting analysis is a useful tool for assessing DNA methylation in fixed tissue samples.

A new agreement with Gamma-Dynacare has made the test available to new customers.

Industry Briefs: Feb 19, 2009

Premium

Proactive, PSI:Bioloyg, Pressure BioSciences, Applied Biomics

BioArray Briefs: 2009.02.17

Premium

SQI Diagnostics, Olink Bioscience, Innova Biosciences, Copenhagen University, Fujirebio Diagnostics, Uppsala University, Integromics, Gene Logic, Ocimum Biosolutions

The three-year project, called Proactive, will be coordinated by Olink Bioscience of Uppsala, Sweden.

The data, which the company said represent the first proof of activity of an oral RNAi drug, set the stage for an investigational new drug application filing later this year.

IP Update: Feb 5, 2009

Premium

USPTO Publishes Seven RNAi-Related Patent Applications

Without specific guidance from the FDA regarding KRAS testing, drugmakers Bristol-Myers Squibb and Amgen are facing lower sales of their colorectal cancer drugs Erbitux and Vectibix, and may need to get creative in how they market their drugs to patients and doctors.

New Product Watch: Feb 3, 2009

Premium

Navigenics, ImaGenes, Ocimum Biosolutions

While Helicos and Rosetta Genomics rose, shares of Cepheid were hit by its forecast of lower revenues. But, overall, the GWDN Index managed to gain ground while the broader market fell.

Pages

The Washington Post reports on researchers' efforts to determine the effect of an increasingly common SARS-CoV-2 mutation.

Florida Politics reports Florida's law barring life, long-term care, and disability insurers from using genetic information in coverage decisions went into effect at the beginning of July.

A new analysis finds a link between popular media coverage of a scientific study and how often that paper is cited.

In Nature this week: CRISPR approaches to editing plant genomes, way to speed up DNA-PAINT, and more.